Mirvetuximab Soravtansine
Records for this ingredient, by country (identity only).
ATC L01FX26 · 11 markets · 12 records
AU 2 records · 1 shown of 1
- 100 mg per mL / per unit basis not statedinjectionELAHERE mirvetuximab soravtansine 100 mg/20 mL concentrate solution for intravenous infusion vial
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
US 1 records · 1 shown of 1
- 5 mg per mL / per unit basis not statedinjectionELAHERE
GB 1 records · 1 shown of 1
- 100 mg/20 mLinjectionElahere 100mg/20ml concentrate for solution for infusion vials
CA 1 records · 1 shown of 1
- 5 mg/1 mLliquidELAHERE
SG 1 records · 1 shown of 1
- 100 mg/20 mLinjectionELAHERE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/20ML
ES 1 records · 1 shown of 1
- 5 mg/1 mLinjectionELAHERE
TW 1 records · 1 shown of 1
- 5 mg per mL / per unit basis not statedinjectionELAHERE solution for infusion 5 mg/mL艾樂延靜脈輸注液5 mg/mL
CZ 1 records · 1 shown of 1
- 5 mg per mL / per unit basis not statedinjectionELAHERE
EU 1 records · 0 shown of 0
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
FR 1 records · 1 shown of 1
- 5 mg/1 mLinjectionELAHERE 5 mg/mL, solution à diluer pour perfusion
Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.
| Strength / form / release | US | GB | CA | AU | SG | ES | TW | CZ | EU | FR |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 mg per mL / per unit basis not stated cannot compare injection | ELAHERE | ELAHERE solution for infusion 5 mg/mL 艾樂延靜脈輸注液5 mg/mL | ELAHERE | |||||||
| 100 mg/20 mL injection | Elahere 100mg/20ml concentrate for solution for infusion vials | ELAHERE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/20ML | ||||||||
| 5 mg/1 mL injection | ELAHERE | ELAHERE 5 mg/mL, solution à diluer pour perfusion | ||||||||
| 5 mg/1 mL liquid | ELAHERE | |||||||||
| 100 mg per mL / per unit basis not stated cannot compare injection | ELAHERE mirvetuximab soravtansine 100 mg/20 mL concentrate solution for intravenous infusion vial | |||||||||
unknown | ELAHERE | ELAHERE |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
3 more strength/form rows are recorded only in GB · CA · SG · ES · FR and are not shown in this table. Hay 3 filas de concentración/forma registradas solo en GB · CA · SG · ES · FR que no se muestran en esta tabla. 另有 3 个规格/剂型仅在 GB · CA · SG · ES · FR 有记录(未在本表显示)。 另有 3 個規格/劑型僅在 GB · CA · SG · ES · FR 有記錄(未在本表顯示)。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.